DiaGenic last week presented prototypes for its early diagnostic test for Alzheimer’s disease.
The gene expression test, which analyzes peripheral blood to detect early onset of Alzheimer’s, was unveiled at the International Conference on Alzheimer’s and Parkinson’s Diseases in Salzburg, Austria.
DiaGenic’s diagnostic is based on CodeLink customized multiassay bioarrays as well as TaqMan RT-PCR technology.
“The results from both prototypes fully meet the criteria for diagnostic use,” the company said.
“The data presented by DiaGenic suggest that this strategy for biomarker discovery may pay off,” said Sam Gandy, a professor at the Farber Institute for Neurosciences, in a statement. “There is a clear need for a better and earlier diagnosis of Alzheimer’s patients.”
CombiMatrix said this week that its CombiMatrix Molecular Diagnostics subsidiary has launched the second version of its Constitutional Genetic Array Test (CA850).
The test uses the company’s new bacterial artificial chromosome array, which includes over 200 new, validated probes obtained through the company’s partnership with the Center for Applied Genomics, in Toronto.
The CA850, which can identify over 50 common genetic disorders in one test, has now been clinically validated for use in both postnatal and prenatal analyses by CMDX, the company said.
Last week, CMDX announced that it is now offering HemeScan, an array comparative genomic hybridization assay designed to detect prognostic markers in chronic lymphocytic leukemia. The test is now available to the clinical community through both routine clinical sample processing as well as through CMDX's Technical Only Program for reference laboratories, CMBX said.
HemeScan is a bacterial artificial chromosome array designed to identify known prognostic genomic imbalances relevant to the clinical course of chronic lymphocytic leukemia, according to CMBX. The company said it anticipates launching other array CGH-based oncology diagnostics and prognostics in coming months.